STING1 and neoplasm: Understanding the co-regulation of bacterial and immune compartments may lead to improved tumour targeting and therapeutic payload release specific to immune components by engineered EcN in the future, as exemplified by the Synlogic approach described above that utilises host phagocytic pathways to activate the STING pathway and prevent tumourigenesis.